4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts rate 4D Molecular Therapeutics “Moderate Buy”: Eight of 11 analysts recommend buying the stock, with one strong-buy, one hold and one sell rating. The average 12-month price target is $28.56 versus a recent share price of $14.68.
• Quarterly results slightly missed expectations: The company reported a loss of $1.04 per share versus the $1.02 consensus estimate, while revenue of $3.78 million exceeded expectations. Analysts project a full-year loss of $4.07 per share.
• Institutional ownership is substantial, but insiders have been selling: Institutions and hedge funds own 99.27% of shares, with Jupiter Topco and BlackRock among recent investors. Insiders sold 257,491 shares worth approximately $3.04 million over the past 90 days.

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $28.5556.

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 target price on the stock in a report on Monday. Chardan Capital upgraded 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $14.68 on Friday. The stock has a market capitalization of $810.92 million, a PE ratio of -5.58 and a beta of 2.74. The business's fifty day moving average price is $12.73 and its 200 day moving average price is $10.81. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. 4D Molecular Therapeutics has a 12-month low of $6.47 and a 12-month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Equities research analysts forecast that 4D Molecular Therapeutics will post -4.07 EPS for the current year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares of the company's stock, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Kirn sold 114,746 shares of the firm's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 257,491 shares of company stock valued at $3,039,990. 7.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jupiter Topco LLC acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $76,466,000. Janus Henderson Group PLC increased its stake in 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock valued at $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. acquired a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $60,463,000. Trails Edge Capital Partners LP bought a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $29,631,296. Finally, Armistice Capital LLC lifted its stake in shares of 4D Molecular Therapeutics by 76.6% in the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company's stock worth $14,520,000 after acquiring an additional 840,000 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.